Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Depreciation & Amortization (CF) (2016 - 2025)

Avanos Medical's Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $11.1 million for Q4 2024.

  • For Q4 2024, Depreciation & Amortization (CF) fell 3.48% year-over-year to $11.1 million; the TTM value through Dec 2024 reached $45.5 million, down 1.3%, while the annual FY2025 figure was $38.9 million, 14.51% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2024 was $11.1 million at Avanos Medical, down from $11.7 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $13.4 million in Q4 2022 and bottomed at $9.5 million in Q2 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $11.1 million (2022), against an average of $11.0 million.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 41.05% in 2022 before it fell 14.18% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $10.8 million in 2020, then dropped by 12.04% to $9.5 million in 2021, then soared by 41.05% to $13.4 million in 2022, then dropped by 14.18% to $11.5 million in 2023, then fell by 3.48% to $11.1 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Depreciation & Amortization (CF) are $11.1 million (Q4 2024), $11.7 million (Q3 2024), and $11.3 million (Q2 2024).